• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Ocugen Inc.

    6/18/24 4:29:04 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OCGN alert in real time by email
    DEFA14A 1 tm2417451d1_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant x

     

    Filed by a Party other than the Registrant  ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement
       
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ¨ Definitive Proxy Statement
       
    x Definitive Additional Materials
       
    ¨ Soliciting Material under §240.14a-12

     

     

     

    Ocugen, Inc.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    x No fee required.
       
    ¨ Fee paid previously with preliminary materials.
       
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

     

     

     

    11 Great Valley Parkway

    Malvern, PA 19355

     

    SUPPLEMENT DATED JUNE 18, 2024 TO THE

    NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

    AND

    PROXY STATEMENT

    FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS

    To Be Held June 28, 2024

     

    This Supplement provides updated information with respect to the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of Ocugen, Inc. (the “Company”) to be held on June 28, 2024.

     

    On May 28, 2024, the Company filed with the Securities and Exchange Commission (the “SEC” or the “Commission”) and made available to its stockholders a Notice of Annual Meeting of Stockholders and Proxy Statement (collectively, the “Notice and Proxy Statement”) for the Annual Meeting.

     

    This Supplement describes a recent change with respect to the Company’s independent registered public accounting firm. The information in this Supplement is in addition to the information provided by the Notice and Proxy Statement and, except for the changes referenced herein, this Supplement does not modify any other information set forth in the Notice and Proxy Statement.

     

    Removal of Proposal 2 from Stockholder Consideration

     

    On June 6, 2024, we announced that subsequent to filing of our Annual Report on Form 10-K for the year ended December 31, 2023 and the Proxy Statement for the Company’s Annual Stockholder Meeting, the Audit Committee (“Audit Committee”) of the Board of Directors of the Company authorized management to initiate a strategic request-for-proposal process soliciting proposals from accounting firms to provide audit services to the Company as its independent registered public accounting firm for the fiscal year ending December 31, 2024. Management requested proposals from several independent registered public accounting firms, including Ernst & Young LLP (“EY”), the Company’s current independent registered public accounting firm, in the process.

     

    On May 31, 2024, EY notified the Company of its decision to decline to participate in the request-for-proposal process and to decline to stand for re-election as the Company’s independent registered public accounting firm for fiscal year 2024, which decision was not the result of any disagreement with the Company. EY will cease providing services following the filing of the Form 10-Q for the quarter ending June 30, 2024.

     

    As a result, the Company is removing Proposal 2 from the agenda for the Annual Meeting, which called for a vote on the ratification of the appointment of EY as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The Company’s request-for-proposal process is currently ongoing and will announce the appointment of the independent registered accounting firm once a new firm is engaged. At this time, the Company does not intend to submit at the Annual Meeting any other proposal for ratification of the appointment of a new independent registered public accounting firm.

     

     

     

     

    Voting Matters

     

    If you have already submitted your proxy or provided voting instructions, you do not need to take any action unless you wish to change your vote.

     

    The Company will not make available or distribute, and you do not need to submit, a new proxy card or provide new voting instructions solely as a result of the removal of Proposal 2. Proxies and voting instructions returned by stockholders will remain valid and will be voted at the Annual Meeting unless revoked, except that any votes cast with respect to Proposal 2 will be disregarded. If you have not yet submitted your proxy or provided your voting instructions, please complete the proxy or submit instructions, disregarding Proposal 2.

     

    None of the other agenda items presented in the Notice and Proxy Statement, or votes cast thereon, are affected by this Supplement. Information regarding how to vote your shares, or change your vote, is available in the Proxy Statement. The Notice and Proxy Statement and this Supplement are available at www.proxyvote.com. This Supplement is being made available on or about June 18, 2024.

     

    Supplemental Disclosure for the Proxy Statement

     

    The Company is providing the following information, which has been reported by the Company in a Current Report on Form 8-K that was filed with the SEC on June 6, 2024, as supplemental disclosure to the Proxy Statement.

     

    The reports of EY on the Company’s consolidated financial statements for the fiscal years ended December 31, 2023 and 2022 did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that the audit reports of EY on the Company’s consolidated financial statements as of and for the years ended December 31, 2023 and 2022 contained an explanatory paragraph which noted that the Company has suffered recurring losses from operations and there was substantial doubt as to the Company’s ability to continue as a going concern, and the audit report of EY on the Company’s consolidated financial statements as of and for the year ended December 31, 2023 contained an explanatory paragraph related to the restatement of the 2022 consolidated financial statements.

     

    During the years ended December 31, 2023 and 2022, and the subsequent interim period through May 31, 2024, there were (i) no disagreements between the Company and EY on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which, if not resolved to EY’s satisfaction, would have caused EY to make reference to the subject matter of the disagreement in connection with its report for such years, and (ii) no “reportable events” as defined in Item 304(a)(1)(v) of Regulation S-K for such years and subsequent interim period through May 31, 2024, except for EY’s communication of the material weakness in internal control over financial reporting as of December 31, 2023, as described in Part II, Item 9A (Controls and Procedures) of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, relating to the design and operating effectiveness of controls over the accounting for collaborative arrangements.

     

     

     

    Get the next $OCGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OCGN

    DatePrice TargetRatingAnalyst
    10/15/2024$4.00Buy
    Maxim Group
    3/1/2023$3.50Neutral → Buy
    Chardan Capital Markets
    8/23/2022$5.00Buy
    Mizuho
    6/15/2022$8.00Buy
    ROTH Capital
    6/2/2022$4.50Overweight
    Cantor Fitzgerald
    2/28/2022$10.00 → $8.00Buy
    HC Wainwright & Co.
    7/26/2021Outperform
    Noble Capital Markets
    More analyst ratings

    $OCGN
    SEC Filings

    View All

    Ocugen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Ocugen, Inc. (0001372299) (Filer)

    2/9/26 7:59:25 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Ocugen Inc.

    SCHEDULE 13G - Ocugen, Inc. (0001372299) (Subject)

    1/30/26 2:16:36 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Ocugen, Inc. (0001372299) (Filer)

    1/23/26 8:12:02 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OCGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $OCGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

    MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this

    2/9/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

    MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced underwritten registered direct offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share of common stock for net proceeds of $20.85 million, after deducting commissions and other estimated offering expenses payable by Ocugen. The financing was led by RTW Investments, with additional participation from new and existing investors. Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital

    1/23/26 8:00:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

    MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share of common stock for gross proceeds of $22.5 million, before deducting commissions and other estimated offering expenses payable by Ocugen. The offering is expected to close on or about January 22, 2026, subject to the satisfaction of customary closing conditions. All of the securities to be sold in the offering are being offered by Ocugen. The financing is being led by RTW Investments, with additional par

    1/21/26 8:32:20 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Maxim Group initiated coverage on Ocugen with a new price target

    Maxim Group initiated coverage of Ocugen with a rating of Buy and set a new price target of $4.00

    10/15/24 8:07:55 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen upgraded by Chardan Capital Markets with a new price target

    Chardan Capital Markets upgraded Ocugen from Neutral to Buy and set a new price target of $3.50

    3/1/23 9:04:17 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mizuho initiated coverage on Ocugen with a new price target

    Mizuho initiated coverage of Ocugen with a rating of Buy and set a new price target of $5.00

    8/23/22 7:19:06 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OCGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Musunuri Shankar was granted 3,123,201 shares, increasing direct ownership by 170% to 4,955,924 units (SEC Form 4)

    4 - Ocugen, Inc. (0001372299) (Issuer)

    1/6/26 5:20:32 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Accounting Officer Ramachandran Ramesh was granted 207,300 shares, increasing direct ownership by 11,517% to 209,100 units (SEC Form 4)

    4 - Ocugen, Inc. (0001372299) (Issuer)

    1/6/26 5:20:14 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 3 filed by new insider Chandrasekhar Satishchandran

    3/A - Ocugen, Inc. (0001372299) (Issuer)

    6/12/25 4:28:45 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OCGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fernandes Prabhavathi bought $9,095 worth of shares (10,000 units at $0.91) (SEC Form 4)

    4 - Ocugen, Inc. (0001372299) (Issuer)

    12/2/24 4:15:25 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Castillo Kirsten bought $22,848 worth of shares (25,000 units at $0.91), increasing direct ownership by 50% to 75,000 units (SEC Form 4)

    4 - Ocugen, Inc. (0001372299) (Issuer)

    11/26/24 4:50:10 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OCGN
    Leadership Updates

    Live Leadership Updates

    View All

    Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

    MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). "Mrs. Johnson-Greene's diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen's CFO," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "We look forward to her leadership as we enter into a transformative time at Ocugen, beginning with the submission of the first of three Biologics License Applications (BLAs) this

    2/9/26 7:02:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

    MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen, will speak during the workshop titled, "U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks." This two-day event will take place from September 9-11, 2024 in New Delhi, India. "It is an honor to join the impressive group of thought leaders in this groundbreaking forum," said Dr. Musunuri. "There are endless opportunities to leverage the bes

    9/9/24 6:30:12 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen Set to Join Russell 3000® Index Effective June 28, 2024

    MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after the market closes on June 28, 2024. "Inclusion of Ocugen to the Russell 3000® Index is our latest milestone, adding to what has already been a transformational year for the Company with three of our game-changing modifier gene therapies targeting

    5/28/24 7:02:39 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OCGN
    Financials

    Live finance-specific insights

    View All

    Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

    MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with KOLs and Ocugen executive leadership to discuss data from the first half of patients completing one year since treatment in the OCU410 Phase 2 ArMaDa clinical trial at 8:30 a.m. ET on Thursday, January 15, 2026. Study investigators leading the webcast include: Arshad M. Khanani, MD, MA, FASRS, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates and Clinical Professor at the University of Nevada, Reno School

    1/13/26 7:00:00 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

    MALVERN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's third quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, November 5, 2025. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details: Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callersConference ID: 3029428Webcast: Available on the events section of

    10/23/25 7:30:30 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ocugen Provides Business Update with Second Quarter 2025 Financial Results

    Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in OCU410ST Phase 2/3 GARDian3 pivotal confirmatory clinical trialActively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial and on track for 2026 BLA filingOrthoCellix reverse merger intended to unlock the value of NeoCart/regenerative cell therapies and enable the Company to focus capital on modifier gene therapy platformSigned binding term sheet for exclusive Korean rights to OCU400 with upfront fees and near-term development milestone payments totaling up to $11 million MALVERN, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene

    8/1/25 8:25:22 AM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $OCGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

    SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

    11/12/24 4:59:47 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocugen Inc.

    SC 13G/A - Ocugen, Inc. (0001372299) (Subject)

    11/4/24 1:43:41 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Ocugen Inc.

    SC 13G - Ocugen, Inc. (0001372299) (Subject)

    10/16/24 12:41:30 PM ET
    $OCGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care